✦ LIBER ✦

Clinical course of ovarian cancer after two salvage regimens

✍ Scribed by C. Nagel; J. Street; S. Kehoe; D. Richardson; D. Miller; J. Lea

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Salvage bevacizumab (rhuMAB VEGF)-based

✍ Bradley J. Monk; Ernest Han; Carol A. Josephs-Cowan; Gordon Pugmire; Robert A. B 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Clinical courses of patients with ovaria

📂 Article 📅 1990 🏛 Elsevier Science ⚖ 173 KB

Epirubicin and paclitaxel (EPI-TAX regim

✍ Isabelle Ray-Coquard; Thomas Bachelot; Jean-Paul Guastalla; Éric Levy; Jean-Domi 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Prognostic factors: Cisplatin regimens f

✍ HW Bruckner; CJ Cohen; E Feuer 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Clinical analysis of HCPT plus FOLFOX4 r

✍ Xiaoqiang Fan; Xijian Zhou; Xiangyong Li; Xinyu Tang; Rengui Zhou; Dejian Pan 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 74 KB

Clinical Follow-Up Strategies after Pote

✍ G. Harmandayan; K.S. Virgo; F. Gao; D.G. Mutch; F.E. Johnson 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB